EP0449972A4 - Triple stranded nucleic acid and methods of use - Google Patents

Triple stranded nucleic acid and methods of use

Info

Publication number: EP0449972A4
Authority: EP; European Patent Office
Prior art keywords: synthetic oligonucleotides; dna; bind; duplex; target sequences
Prior art date: 1988-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19900901460

Other languages

English (en)

Other versions

EP0449972A1 (de

Inventor

Michael Edward Hogan

Donald Joseph Kessler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baylor College of Medicine

Original Assignee

Baylor College of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-20

Filing date

1989-12-20

Publication date

1992-03-18

1989-12-20 Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine

1991-10-09 Publication of EP0449972A1 publication Critical patent/EP0449972A1/de

1992-03-18 Publication of EP0449972A4 publication Critical patent/EP0449972A4/en

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract 6
150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 4
230000000295 complement effect Effects 0.000 abstract 3
239000002773 nucleotide Substances 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01034—Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)

EP19900901460 1988-12-20 1989-12-20 Triple stranded nucleic acid and methods of use Pending EP0449972A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28735988A	1988-12-20	1988-12-20
US287359		1988-12-20

Publications (2)

Publication Number	Publication Date
EP0449972A1 EP0449972A1 (de)	1991-10-09
EP0449972A4 true EP0449972A4 (en)	1992-03-18

Family

ID=23102554

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP19900901460 Pending EP0449972A4 (en)	1988-12-20	1989-12-20	Triple stranded nucleic acid and methods of use
EP89313391A Expired - Lifetime EP0375408B1 (de)	1988-12-20	1989-12-20	Verfahren zur Herstellung synthetischer Oligonukleotide, die spezifisch an Bestimmungsstellen auf Duplex-DNA-Molekülen binden durch Formen eines kolinearen Triplex, die synthetischen Oligonukleotide und Verfahren zu ihrer Herstellung

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP89313391A Expired - Lifetime EP0375408B1 (de)	1988-12-20	1989-12-20	Verfahren zur Herstellung synthetischer Oligonukleotide, die spezifisch an Bestimmungsstellen auf Duplex-DNA-Molekülen binden durch Formen eines kolinearen Triplex, die synthetischen Oligonukleotide und Verfahren zu ihrer Herstellung

Country Status (10)

Country	Link
EP (2)	EP0449972A4 (de)
JP (1)	JPH04502407A (de)
AT (1)	ATE118818T1 (de)
AU (1)	AU640910B2 (de)
CA (1)	CA2006008C (de)
DE (1)	DE68921315T2 (de)
DK (1)	DK120091A (de)
ES (1)	ES2069598T3 (de)
PT (1)	PT92640B (de)
WO (1)	WO1990006934A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5928863A (en) *	1986-11-26	1999-07-27	Princeton University	Triple-stranded nucleic acids
US5422251A (en) *	1986-11-26	1995-06-06	Princeton University	Triple-stranded nucleic acids
US5849482A (en) *	1988-09-28	1998-12-15	Epoch Pharmaceuticals, Inc.	Crosslinking oligonucleotides
US5721218A (en) *	1989-10-23	1998-02-24	Gilead Sciences, Inc.	Oligonucleotides with inverted polarity
US5399676A (en) *	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
IE20010427A1 (en) *	1990-04-10	2003-03-05	Canji Inc	Gene therapy for cell proliferative diseases
WO1991018997A1 (en) *	1990-05-25	1991-12-12	Gilead Sciences, Inc.	Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna
EP0463712A3 (en) *	1990-06-27	1992-04-08	University Patents, Inc.	Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5734022A (en) *	1990-08-01	1998-03-31	The Johns Hopkins University	Antibodies to a novel mammalian protein associated with uncontrolled cell division
WO1992009705A1 (en) *	1990-11-23	1992-06-11	Gilead Sciences, Inc.	Triplex-forming oligomers containing modified bases
WO1992011390A1 (en) *	1990-12-17	1992-07-09	Idexx Laboratories, Inc.	Nucleic acid sequence detection by triple helix formation
US5683874A (en) *	1991-03-27	1997-11-04	Research Corporation Technologies, Inc.	Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US6136601A (en) *	1991-08-21	2000-10-24	Epoch Pharmaceuticals, Inc.	Targeted mutagenesis in living cells using modified oligonucleotides
JPH06510203A (ja) *	1991-08-30	1994-11-17	ザ・ジョーンズ・ホプキンス・ユニバーシティ	プリン塩基類似体を含むヌクレオシドオリゴマーを用いる二重鎖ｄｎａの三重らせん複合体の形成
IL103311A0 (en) *	1991-10-07	1993-03-15	Univ Johns Hopkins	Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
WO1993009127A1 (en) *	1991-11-07	1993-05-13	Gilead Sciences, Inc.	Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
US5594121A (en) *	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) *	1991-11-26	2000-06-11	Isis Pharmaceuticals Inc	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) *	1991-11-26	1993-06-28	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) *	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US5616461A (en) *	1992-05-14	1997-04-01	Dana-Farber Cancer Institute	Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US6403302B1 (en)	1992-09-17	2002-06-11	California Institute Of Technology	Methods and compositions for triple helix formation
WO1994007367A1 (en) *	1992-09-29	1994-04-14	Apollon, Inc.	Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
EP0674705A4 (de) *	1992-11-09	1997-11-26	Univ Jefferson	Antisense-oligonukleotide zur hemmung der expression mutierter gene und wildtypgene des collagens.
WO1994013793A1 (en) *	1992-12-04	1994-06-23	Apollon, Inc.	Compounds and methods for the treatment of leukemias
AU684774B2 (en) *	1992-12-08	1998-01-08	Genta Incorporated	Formation of triple helix complexes using a novel motif
WO1994017092A1 (en) *	1993-01-26	1994-08-04	Microprobe Corporation	Bifunctional crosslinking oligonucleotides adapted for linking to a desired gene sequence of invading organism or cell
US6323185B1 (en)	1993-04-23	2001-11-27	The United States Of America As Represented By The Department Of Health And Human Services	Anti-viral guanosine-rich oligonucleotides and method of treating HIV
US6288042B1 (en)	1993-04-23	2001-09-11	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich tetrad forming oligonucleotides
US5567604A (en) *	1993-04-23	1996-10-22	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich oligonucleotides
KR960703170A (ko)	1993-06-23	1996-06-19	알버트 디. 프리센.	안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
US5962426A (en) *	1993-06-25	1999-10-05	Yale University	Triple-helix forming oligonucleotides for targeted mutagenesis
ATE161541T1 (de)	1993-06-25	1998-01-15	Univ Yale	Chemische-modifizierte oligonukleotide für site- spezifisches mutagenesis
WO1995011253A1 (en) *	1993-10-18	1995-04-27	The Walter And Eliza Hall Institute Of Medical Research	A method for enhancing neurone survival and agents useful for same
US5488039A (en) *	1994-01-10	1996-01-30	Abbott Laboratories	Method for the production of an enteral formula containing ribo-nucleotides
US5602109A (en) *	1994-01-10	1997-02-11	Abbott Laboratories	Method to enhance the immune system of a human
US5492899A (en) *	1994-01-10	1996-02-20	Abbott Laboratories	Infant nutritional formula with ribo-nucleotides
US5700590A (en) *	1994-01-10	1997-12-23	Abbott Laboratories	Nutritional formula with ribo-nucleotides
US6136858A (en) *	1994-01-10	2000-10-24	Abbott Laboratories	Infant formula and methods of improving infant stool patterns
US5808037A (en) *	1995-09-15	1998-09-15	Ramareddy Venkata Guntaka	Oligomers which inhibit expression of collagen genes
US6156513A (en) *	1995-09-15	2000-12-05	Ramareddy V. Guntaka	Oligmers which inhibit expression of collagen genes
US5780611A (en) *	1995-09-15	1998-07-14	Ramareddy Venkata Guntaka	Oligomers which inhibit expression of collagen genes
FR2746412B1 (fr) *	1996-03-21	1998-06-12	Rhone Poulenc Rorer Sa	Purification d'adn plasmidique de qualite pharmaceutique
US6312925B1 (en)	1997-05-08	2001-11-06	Epoch Pharmaceuticals, Inc.	Methods and compositions to facilitate D-loop formation by oligonucleotides
US6930175B1 (en)	1997-12-12	2005-08-16	The Johns Hopkins University School Of Medicine	Gene family with transformation modulating activity
US8114850B2 (en)	1999-04-08	2012-02-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
JP2002541264A (ja) *	1999-04-08	2002-12-03	ユーエイビー・リサーチ・ファウンデーション	冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US20030114410A1 (en)	2000-08-08	2003-06-19	Technion Research And Development Foundation Ltd.	Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
FR2822156A1 (fr) *	2001-03-16	2002-09-20	Centre Nat Rech Scient	Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications
US8129514B2 (en)	2003-06-19	2012-03-06	Evogene Ltd.	Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
EP1636333A4 (de)	2003-06-19	2007-10-24	Evogene Ltd	Nukleotidsequenzen zur regulation der genexpression in pflanzentrichomen sowie diese verwendende konstrukte und verfahren
ES2435774T3 (es)	2005-07-07	2013-12-23	Yissum Research Development Company, Of The Hebrew University Of Jerusalem	Agentes de ácido nucleico para la regulación negativa de H19, y métodos de uso del mismo
US8658608B2 (en)	2005-11-23	2014-02-25	Yale University	Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2008087641A2 (en)	2007-01-16	2008-07-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem	H19 silencing nucleic acid agents for treating rheumatoid arthritis
EP2200628A2 (de)	2007-07-15	2010-06-30	Yitzchak Hillman	Behandlung von krankheiten über antimikrobielle peptide oder ihre inhibitoren
IL184627A0 (en)	2007-07-15	2008-12-29	Technion Res & Dev Foundation	Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2700141T3 (es)	2007-08-02	2019-02-14	Gilead Biologics Inc	Anticuerpos inhibidores LOXL2 y usos de los mismos
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009124150A2 (en)	2008-04-01	2009-10-08	Biosearch Technologies, Inc.	Stabilized nucleic acid dark quencher-fluorophore probes
AU2009298802A1 (en)	2008-09-23	2010-04-08	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010080769A2 (en)	2009-01-06	2010-07-15	Arresto Biosciences, Inc.	Chemotherapeutic methods and compositions
DK2414542T3 (da)	2009-03-30	2017-11-27	Tel Hashomer Medical Res Infrastructure & Services Ltd	Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
SG178845A1 (en)	2009-08-21	2012-04-27	Gilead Biologics Inc	Catalytic domains from lysyl oxidase and loxl2
MX2012002189A (es)	2009-08-21	2012-03-16	Beeologics Inc	Prevencion y cura de las enfermedades de los insectos beneficiosos a traves de moleculas.
WO2011030332A2 (en)	2009-09-08	2011-03-17	Yeda Research And Development Co. Ltd.	Methods for hematopoietic precursor mobilization
WO2011030329A1 (en)	2009-09-10	2011-03-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of treating tumors
EP3272869B1 (de)	2009-10-14	2020-06-24	Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.	Zusammensetzungen zur bekämpfung von varroa-milben bei bienen
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
BR112012019693A2 (pt)	2010-02-04	2017-06-20	Gilead Biologics Inc	anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
RU2012148398A (ru)	2010-04-18	2014-05-27	Иеда Рисеч Энд Девелопмент Ко. Лтд.	МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011158243A2 (en)	2010-06-16	2011-12-22	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of diagnosing and treating cancer
CN103210082A (zh)	2010-09-15	2013-07-17	雷蒙特亚特特拉维夫大学有限公司	扩增胰岛β细胞和使其再分化的方法
EP2627766B1 (de)	2010-10-17	2016-05-25	Yeda Research and Development Co. Ltd.	Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen
US9415103B2 (en)	2011-06-14	2016-08-16	Yeda Research And Development Co. Ltd.	Combination therapy to prevent DCIS formation and progression to breast cancer
EP2741753A2 (de)	2011-08-09	2014-06-18	Yeda Research and Development Co. Ltd.	Herunterregulierung von mir-7 zur förderung der beta-zellen-differenzierung und insulinproduktion
WO2013061328A2 (en)	2011-10-27	2013-05-02	Yeda Research And Development Co. Ltd.	Method of treating cancer
US9617331B2 (en)	2011-11-27	2017-04-11	Yeda Research And Development Co. Ltd.	Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide
EP2844745A2 (de)	2012-02-22	2015-03-11	Brainstem Biotec Ltd.	Erzeugung von neuralen stammzellen und motorneuronen
RU2015149680A (ru)	2013-04-21	2017-05-24	Йеда Ресеарч Энд Девелопмент Ко. Лтд.	Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
RU2703498C2 (ru)	2013-07-19	2019-10-17	Монсанто Текнолоджи Ллс	Композиции и способы борьбы с leptinotarsa
HUE070313T2 (hu)	2013-11-04	2025-05-28	Greenlight Biosciences Inc	Ízeltlábú paraziták és kártevõfertõzöttség szabályozására szolgáló készítmények és eljárások
AU2015212341A1 (en)	2014-02-03	2016-09-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Use of Casein kinase I inhibitors for depleting stem cells
BR112016022711A2 (pt)	2014-04-01	2017-10-31	Monsanto Technology Llc	composições e métodos para controle de pragas de inseto
RU2021123470A (ru)	2014-07-29	2021-09-06	Монсанто Текнолоджи Ллс	Композиции и способы борьбы с насекомыми-вредителями
CN108064274A (zh)	2014-07-30	2018-05-22	耶达研究及发展有限公司	用于培养多能干细胞的培养基
WO2016030899A1 (en)	2014-08-28	2016-03-03	Yeda Research And Development Co. Ltd.	Methods of treating amyotrophic lateral scleroses
WO2016079736A2 (en)	2014-11-17	2016-05-26	Yeda Research And Development Co. Ltd.	Methods of treating diseases related to mitochondrial function
JP6942632B2 (ja)	2015-01-22	2021-09-29	モンサントテクノロジーエルエルシー	Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
EP3261582B1 (de)	2015-02-26	2021-01-06	Remodeless CV Ltd.	Verfahren und zusammensetzungen in zusammenhang mit leptin-antagonisten
WO2016135732A1 (en)	2015-02-26	2016-09-01	Yeda Research And Development Co. Ltd.	Method of promoting hair growth
CN107683089B (zh)	2015-05-04	2021-03-16	孟山都技术公司	用于控制节肢动物寄生虫和害虫侵扰的组合物和方法
EP3294280A1 (de)	2015-05-11	2018-03-21	Yeda Research and Development Co., Ltd.	Citrinhemmer zur behandlung von krebs
WO2016185457A1 (en)	2015-05-19	2016-11-24	Yeda Research And Development Co. Ltd.	Methods of promoting lymphangiogenesis
EA201792547A1 (ru)	2015-05-21	2018-04-30	Иеда Рисеч Энд Девелопмент Ко. Лтд.	Популяции бактерий для стимуляции состояния здоровья
CA3205381A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
ES2965461T3 (es)	2015-08-03	2024-04-15	Biokine Therapeutics Ltd	Inhibidor de CXCR4 para el tratamiento del cáncer
US11174484B2 (en)	2015-11-10	2021-11-16	B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University	Means and methods for reducing tumorigenicity of cancer stem cells
US10828318B2 (en)	2016-01-06	2020-11-10	Yeda Research And Development Co. Ltd.	Compositions and methods for treating malignant, autoimmune and inflammatory diseases
JP2019508037A (ja)	2016-02-16	2019-03-28	イェールユニバーシティーＹａｌｅＵｎｉｖｅｒｓｉｔ	標的化遺伝子編集を増強するための組成物およびその使用方法
US20190216891A1 (en)	2016-03-06	2019-07-18	Yeda Research And Development Co., Ltd.	Method for modulating myelination
IL247368A0 (en)	2016-08-18	2016-11-30	Yeda Res & Dev	Diagnostic and therapeutic uses of exosomes
WO2018187493A1 (en)	2017-04-04	2018-10-11	Yale University	Compositions and methods for in utero delivery
EP3658158A4 (de)	2017-07-27	2021-04-14	The National Institute for Biotechnology in the Negev Ltd.	Smac/yldiablo-inhibitoren zur behandlung von krebs
IL255664A0 (en)	2017-11-14	2017-12-31	Shachar Idit	Hematopoietic stem cells with enhanced properties
EP3723785A1 (de)	2017-12-17	2020-10-21	Yeda Research and Development Co. Ltd	Komplexe modulatoren des cop9-signalosoms (csn) und deren verwendung
WO2019155465A1 (en)	2018-02-08	2019-08-15	Yeda Research And Development Co. Ltd.	Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
US11648260B2 (en)	2018-03-29	2023-05-16	Technion Research And Development Foundation Limitted	Vesicles comprising a PTEN inhibitor and uses of same
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
WO2020170240A1 (en)	2019-02-21	2020-08-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method for reduction drug-induced nephrotoxicity
AU2020279101B2 (en)	2019-05-17	2025-07-24	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
EP4004548B1 (de)	2019-07-29	2026-01-14	Yeda Research and Development Co. Ltd	Verfahren zur behandlung und diagnose von lungenkrebs
WO2022011214A1 (en)	2020-07-10	2022-01-13	Alnylam Pharmaceuticals, Inc.	Circular sirnas
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
AU2022325816A1 (en)	2021-08-10	2024-03-21	Gamida-Cell Ltd.	Engineered nk cells, methods of their production and uses thereof
EP4522742A2 (de)	2022-05-13	2025-03-19	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
WO2024137756A1 (en) *	2022-12-23	2024-06-27	Hongene Biotech Corporation	Compounds and methods for liquid phase oligonucleotide synthesis
EP4709855A2 (de)	2023-05-12	2026-03-18	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide

1989
- 1989-12-19 CA CA002006008A patent/CA2006008C/en not_active Expired - Fee Related
- 1989-12-20 AT AT89313391T patent/ATE118818T1/de not_active IP Right Cessation
- 1989-12-20 DE DE68921315T patent/DE68921315T2/de not_active Expired - Fee Related
- 1989-12-20 JP JP2502252A patent/JPH04502407A/ja active Pending
- 1989-12-20 EP EP19900901460 patent/EP0449972A4/en active Pending
- 1989-12-20 AU AU48384/90A patent/AU640910B2/en not_active Ceased
- 1989-12-20 EP EP89313391A patent/EP0375408B1/de not_active Expired - Lifetime
- 1989-12-20 ES ES89313391T patent/ES2069598T3/es not_active Expired - Lifetime
- 1989-12-20 PT PT92640A patent/PT92640B/pt not_active IP Right Cessation
- 1989-12-20 WO PCT/US1989/005769 patent/WO1990006934A1/en not_active Ceased
1991
- 1991-06-20 DK DK120091A patent/DK120091A/da not_active Application Discontinuation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 339, no. 6226, June 22, 1989, New York, P. RAJAGOPAL et al. "Triple-strand formation in the homopurine:homopyrimidine DNA oligonucleotides d(G-A)4 and d(T-C)4", pages 637-640 *
NUCLEIC ACIDS RESEARCH, vol. 14, no. 23, December 9, 1986, Oxford, R.D. DRINKWATER et al. "Two human repetitive DNA elements: a new interspersed repeat found in the factor IX gene, and a satellite 11 tandem repeat sequence", page 9541 *
NUCLEIC ACIDS RESEARCH, vol. 16, no. 24, December 23, 1988, Oxford, J.-C. FRANCOISE et al. "Sequence-specific recog- nition of the major groove of DNA by oligodeoxynucleotides via triple helix formation. Footprinting studies", pages 11431-11440 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 84, no. 15, August 1987, Baltimore, USA, S.L. BROITMAN et al. "Formation of the triple-stranded polynucleotide helix, poly(A A U)", pages 5120-5124 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 85, no. 5, March 1988, Baltimore, USA, D. PRASEUTH et al. "Sequence- -specific binding and photo- crosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation", pages 1349-1353 *
SCIENCE, vol. 238, October 30, 1987, Washington DC, H.E. MOSER et al. "Sequence- Specific Cleavage of Double Helical DNA by Triple Helix Formation", pages 645-650 *
SCIENCE, vol. 241, June 22, 1988, Washington DC, M. COONEY et al. "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro", pages 456-459 *

Also Published As

Publication number	Publication date
EP0375408B1 (de)	1995-02-22
JPH04502407A (ja)	1992-05-07
EP0375408A1 (de)	1990-06-27
EP0449972A1 (de)	1991-10-09
PT92640A (pt)	1990-06-29
WO1990006934A1 (en)	1990-06-28
ATE118818T1 (de)	1995-03-15
DE68921315D1 (de)	1995-03-30
DE68921315T2 (de)	1995-08-03
AU4838490A (en)	1990-07-10
DK120091D0 (da)	1991-06-20
CA2006008C (en)	2000-02-15
ES2069598T3 (es)	1995-05-16
AU640910B2 (en)	1993-09-09
DK120091A (da)	1991-06-20
CA2006008A1 (en)	1990-06-20
PT92640B (pt)	1995-09-12

Legal Events

Date	Code	Title	Description
1991-08-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1991-08-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
1991-10-09	17P	Request for examination filed	Effective date: 19910612
1991-10-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE
1992-03-18	A4	Supplementary search report drawn up and despatched	Effective date: 19920128
1992-03-18	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE
1992-09-02	XX	Miscellaneous (additional remarks)	Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89313391.8/0375408 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 22.07.92.

Publication	Publication Date	Title
EP0449972A4 (en)	1992-03-18	Triple stranded nucleic acid and methods of use
EP0828849A4 (de)	2005-01-19	Oligonukleotidliganden mit hoher affinität für wachstumsfaktoren
DE69627698D1 (de)	2003-05-28	Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
ATE239090T1 (de)	2003-05-15	Methode zum generieren von einzelsträngigen dna molekülen
ATE269908T1 (de)	2004-07-15	Methode zur sequenzierung von nukleinsäuren
AU3728093A (en)	1993-09-13	Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
EP0331939A3 (de)	1991-10-30	Verfahren und Zusammensetzungen zum Widerstand gegen Retroviralinfektionen
EP0369360A3 (de)	1991-01-09	Differenzierung von Nukleinsäure-Segmenten auf der Basis von Verschiedenheiten der Nukleotiden
FI893526A0 (fi)	1989-07-21	Material och metod foer oekning av nukleinsyrahybridisering.
EP0285123A3 (de)	1989-02-01	Verfahren zur vollständigen Mutagenese von Nucleinsäuren
DK51092D0 (da)	1992-04-15	Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
DE3850093D1 (de)	1994-07-14	Verfahren zur Amplifizierung von Nukleinsäuren.
ZA903453B (en)	1991-02-27	Method for the synthesis of ribonucleic acid(rna)
Collick et al.	1991	Minisatellite binding protein Msbp-1 is a sequence-specific single-stranded DNA-binding protein
ATE360688T1 (de)	2007-05-15	Dna-fragment, dieses enthaltender rekombinanter vektor und verfahren zur expression von fremdgenen unter dessen verwendung
EP0812911B1 (de)	2004-09-08	Methode zur Bildung makromolekularer Mikrogenpolymeren
Chu et al.	1990	Optimization of the efficiency of cross-linking PtII oligonucleotide phosphorothioate complexes to complementary oligonucleotides
ATE317123T1 (de)	2006-02-15	Reaktiver träger zur bestimmung von dna fragmenten
DE69626032D1 (de)	2003-03-06	Modifizierung von oligonukleotid-primer-sequenzen zum manipilieren der zugabe von nicht-template-nukleotiden
EP1042510A1 (de)	2000-10-11	Methode zur selektion von flankierenden sequenzen, welche die bindungsaffinitäten zu einer ligandenbindestelle beeinflussen
James Shen	1983	Superhetieity induces hypersensitivity of a human polypyrimldine polypurine DNA sequence in the human α2-α1 globin intergenic region to SI nudease digestion-high resolution mapping of the clustered cleavage sites
Holden	1997	Map marks the X (chromosome)
DE68916905D1 (de)	1994-08-25	Spezifische Nukleinsäurefragmente des menschlichen Villingens, ihre Anwendung für diagnostische Zwecke.
ATE296883T1 (de)	2005-06-15	Mn-gen und -protein
GB2302541A (en)	1997-01-22	Method of using mobile priming sites for DNA sequencing